Vaxcyte Inc. (PCVX) News

Vaxcyte Inc. (PCVX): $21.69

-0.07 (-0.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter PCVX News Items

PCVX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PCVX News Highlights

  • PCVX's 30 day story count now stands at 6.
  • Over the past 23 days, the trend for PCVX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • ATHA and WASH are the most mentioned tickers in articles about PCVX.

Latest PCVX News From Around the Web

Below are the latest news stories about Vaxcyte Inc that investors may wish to consider to help them evaluate PCVX as an investment opportunity.

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

-- Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection -- SAN CARLOS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequence

Yahoo | February 23, 2022

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

GlobeNewswire | February 17, 2022

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.

GlobeNewswire | February 10, 2022

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Grant Pickering to its Board of Directors. Mr. Pickering is Chief Executive Officer, co-founder and member of the Board of Directors at Vaxcyte, Inc. (NASDAQ: PCVX), a vaccine innovation company engineering high-fidelity vaccines to prote

Yahoo | January 31, 2022

Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate

Vaxcyte Inc (NASDAQ: PCVX ) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering. The aggregate gross proceeds to Full story available on Benzinga.com

Benzinga | January 13, 2022

Vaxcyte raises $100M capital in stock offering

Vaxcyte (PCVX) has priced its public offering of 2.5M shares of common stock and pre-funded warrants to purchase equal number of shares.The shares and pre-funded warrants are being sold

Seeking Alpha | January 13, 2022

Vaxcyte Announces Pricing of $100 Million Public Offering

SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 2,500,000 shares of common stock and pre-funded warrants to purchase 2,500,000 shares of common stock in the offering. The shares of common stock are being sold at

Yahoo | January 13, 2022

Vaxcyte proposes stock offering (NASDAQ:PCVX)

Vaxcyte (PCVX) starts the direct offering of its common stock and pre-funded warrants where underwriters are to be granted an additional 15% overallotment option. Actual size, price

Seeking Alpha | January 12, 2022

Puma Biotechnology, Marin Software lead aftermarket gainers; Vaxcyte among losers

Gainers: Puma Biotechnology PBYI +16%, Marin Software (MRIN) +9%, Midland States Bancorp (MSBI) +6%, IDEAYA Biosciences (IDYA) +3%, Ironwood Pharmaceuticals (IRWD) +3%.Losers:…

Seeking Alpha | January 12, 2022

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN CARLOS, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purc

Yahoo | January 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4869 seconds.